贝达药业：BPI-572270是一款分子胶抑制剂，目前该项目正推进提交临床研究申请（IND）准备工作

Core Insights - The company is preparing to submit an Investigational New Drug (IND) application for its molecular glue inhibitor BPI-572270 [1] - The CFT8919 project, an oral bioavailable allosteric BiDAC™ degrader, is currently in Phase I clinical trials [1] Group 1 - The company responded to investor inquiries regarding the clinical application timeline for its molecular glue and degrader projects [1] - BPI-572270 is identified as a molecular glue inhibitor, indicating its potential role in targeted therapies [1] - CFT8919 is noted for its oral bioavailability, which may enhance patient compliance and treatment outcomes [1]